Clinical Trial Update: Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy [Phase 4]

View source ↗

Summary

Phase 4 study evaluating rasburicase for treatment or prevention of hyperuricemia associated with tumor lysis syndrome in patients with relapsed or refractory l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Solid Tumors

Drugs mentioned

• ELITEK (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Tumors, Hyperuricemia | Phase 4 | Status: COMPLETED